stockrowRigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.
- Revenue
- +16.5%
- EPS
- −54.8%
- Free cash flow
- +43.9%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow RIGL
Alert me
Rigel Pharmaceuticals, Inc. (RIGL) EV/Sales
As of 6 November 2026, Rigel Pharmaceuticals, Inc. (RIGL) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from 0.0× (March 2015) to 48.0× (September 2018); the current reading is higher than 37% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | 43.53% |
| FY2024 | 1.5× | (29.25%) |
| FY2023 | 2.1× | 22.40% |
| FY2022 | 1.7× | (24.94%) |
| FY2021 | 2.3× | (54.37%) |
| FY2020 | 5.1× | 11.83% |
| FY2019 | 4.6× | (14.17%) |
| FY2018 | 5.3× | (84.49%) |
| FY2017 | 34.2× | 334.55% |
| FY2016 | 7.9× | 56.76% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.8× | 21.58% |
| Jun 2026 | 2.3× | 90.77% |
| Mar 2026 | 1.2× | (43.65%) |
| Dec 2025 | 2.2× | 51.41% |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LTGO Latigo Biotherapeutics Inc compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | 1.5× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 2.0× |
| RIGL Rigel Pharmaceuticals, Inc. | 2.3× |
| SNDX Syndax Pharmaceuticals, Inc. compare | 3.6× |
| GLUE Monte Rosa Therapeutics, Inc. compare | 7.0× |
| AKTS Aktis Oncology, Inc. compare | 36.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)